Impact of humoral immune response against p53 on clinical outcome of High-Grade Serous Ovarian Cancer (HGSOC) patients

被引：0
|
作者：
Garziera, M. [1 ]
Cecchin, E. [1 ]
Montico, M. [1 ]
Roncato, R. [1 ]
Gagno, S. [1 ]
De Mattia, E. [1 ]
Sorio, R. [2 ]
Scalone, S. [2 ]
Poletto, E. [3 ]
Toffoli, G. [1 ]
机构：
[1] Natl Canc Inst, CRO, Expt & Clin Pharmacol Unit, Aviano, Italy
[2] Natl Canc Inst, CRO, Oncol Unit C, Aviano, Italy
[3] Univ Udine, Dept Oncol, Udine, Italy
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
24P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing
    Alexander J. Cole
    Trisha Dwight
    Anthony J. Gill
    Kristie-Ann Dickson
    Ying Zhu
    Adele Clarkson
    Gregory B. Gard
    Jayne Maidens
    Susan Valmadre
    Roderick Clifton-Bligh
    Deborah J. Marsh
    Scientific Reports, 6
  • [32] Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in BRCA/P53 models
    Wyant, Gregory A.
    Perets, Ruth
    Muto, Katherine
    Poole, Barish B.
    Chen, Jin Y. H.
    Ohman, Anders W.
    Setlur, Sunita R.
    Crum, Christopher P.
    Drapkin, Ronny
    Dinulescu, Daniela M.
    CLINICAL CANCER RESEARCH, 2013, 19
  • [33] Rescue of p53 functions by in vitro-transcribed mRNA impedes the growth of high-grade serous ovarian cancer
    Raab, Monika
    Kostova, Izabela
    Pena-Llopis, Samuel
    Fietz, Daniela
    Kressin, Monika
    Aberoumandi, Seyed Mohsen
    Ullrich, Evelyn
    Becker, Sven
    Sanhaji, Mourad
    Strebhardt, Klaus
    CANCER COMMUNICATIONS, 2024, 44 (01) : 101 - 126
  • [34] A p53 activating mutation drives metastatic high-grade serous ovarian cancer arising from the ovary in mice
    Kim, Jaeyeon
    Coffey, Donna M.
    Ma, Lang
    Matzuk, Martin M.
    CANCER RESEARCH, 2014, 74 (19)
  • [35] New immune phenotypes for treatment response in high-grade serous ovarian carcinoma patients
    Torkildsen, Cecilie Fredvik
    Austdal, Marie
    Jarmund, Anders Hagen
    Kleinmanns, Katrin
    Lamark, Eva Karin
    Nilsen, Elisabeth Berge
    Stefansson, Ingunn
    Sande, Ragnar Kvie
    Iversen, Ann-Charlotte
    Thomsen, Liv Cecilie Vestrheim
    Bjorge, Line
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [36] Determinants of resistance and response in high-grade serous ovarian cancer
    Bowtell, David D. L.
    CLINICAL CANCER RESEARCH, 2016, 22
  • [37] Chemotherapy response ccore (CRS) combined with clinical characteristics predict prognosis in high-grade serous ovarian carcinoma (HGSOC) patients with neoadjuvant chemotherapy
    Xu, Qin
    Liu, Jing
    Pan, Junping
    Song, Yanwen
    Luo, Lan
    Hu, Dan
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S185 - S185
  • [38] Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer (HGSOC)
    Durmaz, Irem
    Hedenfalk, Ingrid
    CANCER RESEARCH, 2018, 78 (13)
  • [39] Recombinant Human p53 Adenovirus Injection (rAd-p53) Combined with Chemotherapy for 4 Cases of High-grade Serous Ovarian Cancer
    Qu, Hui
    Xia, Yu
    Li, Xiuqin
    CURRENT GENE THERAPY, 2020, 20 (04) : 313 - 320
  • [40] Toxicity and Therapy Outcome Associations in High-grade Serous Ovarian Cancer
    Deng, F.
    Laasik, M.
    Salminen, L.
    Lapatto, L.
    Huhtinen, K.
    Li, Y.
    Hautaniemi, S.
    Hynninen, J.
    Niemi, M.
    Lehtonen, R.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (SUPPL 1) : S96 - S96
12345